| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1023289568 |
| P356 | DOI | 10.1007/S11926-012-0261-7 |
| P932 | PMC publication ID | 3387490 |
| P698 | PubMed publication ID | 22580894 |
| P5875 | ResearchGate publication ID | 224950145 |
| P2093 | author name string | Marilyn C Pike | |
| Lexy Kelley | |||
| P2860 | cites work | Systematic adjudication of myocardial infarction end-points in an international clinical trial | Q24805625 |
| Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study | Q24805692 | ||
| Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score | Q24817087 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials | Q33343338 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. | Q33489552 | ||
| The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus | Q33692647 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? | Q34147687 | ||
| A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth | Q34309097 | ||
| Treatment of systemic lupus erythematosus with epratuzumab. | Q34580559 | ||
| Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. | Q34613920 | ||
| The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation | Q34669832 | ||
| Blinded independent central review of the progression-free survival endpoint | Q35584061 | ||
| The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus | Q37170754 | ||
| The BILAG-2004 index is sensitive to change for assessment of SLE disease activity | Q37190011 | ||
| Disease-modifying agents for multiple sclerosis: recent advances and future prospects | Q37328280 | ||
| Novel evidence-based systemic lupus erythematosus responder index | Q37356378 | ||
| Employment and work disability in systemic lupus erythematosus: a systematic review. | Q37372208 | ||
| Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus | Q37778652 | ||
| Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial | Q37827218 | ||
| Treatment of systemic lupus erythematosus: new advances in targeted therapy | Q37974990 | ||
| Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations | Q38419844 | ||
| From BILAG to BLIPS--disease activity assessment in lupus past, present and future | Q40724809 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort | Q43474417 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Peripheral neuropathy in systemic lupus erythematosus | Q44922964 | ||
| The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial | Q46557882 | ||
| Systemic lupus erythematosus: clinical manifestations, treatment and economics | Q46686656 | ||
| The inter-rater reliability of estimating the size of burns from various burn area chart drawings | Q47244547 | ||
| Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. | Q51056209 | ||
| SLEDAI-2K for a 30-day window. | Q51799721 | ||
| The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. | Q52884043 | ||
| Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. | Q53159221 | ||
| BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus | Q60699961 | ||
| Validity and reliability of lupus activity measures in the routine clinic setting | Q68086089 | ||
| Classification and definition of major flares in SLE clinical trials | Q73198904 | ||
| Systemic lupus erythematosus disease activity index 2000 | Q77624632 | ||
| Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort | Q85085364 | ||
| P433 | issue | 4 | |
| P921 | main subject | research design | Q1438035 |
| data quality | Q1757694 | ||
| systemic lupus erythematosus | Q1485 | ||
| clinical trial | Q30612 | ||
| P304 | page(s) | 324-333 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? | |
| P478 | volume | 14 |
| Q36669674 | Architecture design of a generic centralized adjudication module integrated in a web-based clinical trial management system |
| Q38799791 | Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser |
| Q37464041 | Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study |
| Q38271939 | Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. |
| Q38840646 | Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. |
| Q38075878 | Systemic lupus erythematosus: an update on current pharmacotherapy and future directions |
| Q39045512 | Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus |
Search more.